Skip to Content

Shulin Li, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
W. T. and Louise Jarrett Moran Distinguished Chair in Pediatric Oncology, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests


Lab interests


1.     IL12 and IL27 signaling on tumorigenesis, progression and metastasis

2.     Biology of IL30 such as liver protection

3.     Discovery of circulating tumor cell markers and genetic defects

4.     Electroporation chemogene therapy for treating tumors in small and large animal model

5.     Stem cell engineering and programming

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 853
Houston, TX 77054
Room Number: SRB MOD2.017
Phone: 713-563-9608
Fax: 713-563-9607

Education & Training

Degree-Granting Education

1993 Washington State University, Pullman, WA, PHD, Cell Wall Biology
1985 Shanxi State University, Shanxi, China, BS, Biological Science

Postgraduate Training

1993-1997 Post doctorate, Molecular Immunology, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX


Academic Appointments

Professor, Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, LA, 6/2007-5/2010
Associate Professor, Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, LA, 1/2003-5/2007
Assistant Professor/Director of Basic Research, Department of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock, AR, 6/1999-12/2001

Administrative Appointments/Responsibilities

Committee Chair, American Society of Gene Therapy, Immune Response o Cell and Gene Therapy, Philadelphia, PA, 2011-2012
Committee Chair, American Society of Gene Therapy, Physical Gene and Cell Therapy and Vectrology Section, Washington, DC, 2009-2010
Director of Basic Research, Department of Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, 1999-2001

Endowed Positions

Paula & Milton Endowed Professor, Department of Veterinary Medicine and Surgery, Louisiana State University, Baton Rouge, LA, 6/2007-5/2010

Honors and Awards

2007 Distinguished Faculty Scholar Award, School of Veterinary Medicine, Louisiana State University
2005 Pfizer Award for Research Excellence

Selected Publications

Peer-Reviewed Original Research Articles

1. Luk B, Fang R, Hu C-M, Copp J, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. Safe and immunocampatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 6(7):1004-11, 4/2016. PMID: 27217833.
2. Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of immunomodulatory Interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clin Cancer Res. e-Pub 3/2016. PMID: 26979394.
3. Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in Concert with an Interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 63(3):1000-12, 3/2016. PMCID: PMC4764463.
4. Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2/1/2016. e-Pub 1/19/2016. PMCID: PMC4731168.
5. Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol. e-Pub 1/2016. NIHMSID: NIHMS764287.
6. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. Journal of the National Cancer Institute 107(8), 5/2015. PMID: 25971300.
7. Cutrera J, King G, Jones P, Gumpel E, Kicenuik K, Xia X, Li S. Safe and Effective Treatment of Spontaneous Neoplasms with Interleukin 12 Electro-Chemo-Gene Therapy. Journal of Cellular and Molecular Medicine 19(3):664-675, 3/2015. PMCID: PMC4369822.
8. Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CK11b positive bone marrow derived stromal cells. Cell Communications and Signaling 13(14), 2/2015.
9. Mitra A, Li S. Cell-surface Valentin (slim): A mislocalized protein for isolating csVimentin+CD133- novel stem-like hepatocellular carcinoma cells expressing EMT markers. International Journal of Cancer. e-Pub 12/2014. PMCID: PMC4429009.
10. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, and Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clinical Cancer Research, 12/2014. PMCID: PMC4334736.
11. Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S. IL30 attenuates liver fibrosis through inducing NKG2D-Rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 60(6):(IL27p28), 12/2014. e-Pub 10/2014. PMCID: PMC4245364.
12. Lu J, Zhao W, Huang Y, Liu H, Marquez R, Gibbs R, Li J, Venkatarmanan R, Xi L, Li S, Li S. Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier. Molecular Pharmaceutics 11(11):4164-78, 11/2014. PMCID: PMC4224520.
13. Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule- and Cell-Surface Vimentin-Based Methods for Monitoring Breast Cancer Therapeutic Response. Clinical Chemistry 61(1):259-266, 10/2014. PMID: 25336717.
14. Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Molecular Cancer, 1/2014. PMCID: PMC3938086.
15. Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biological Procedures Online, 1/2014. PMCID: PMC3916315.
16. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research(6):1645-1650, 1/2014. PMCID: PMC3959622.
17. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions. Current Gene Therapy 15(1):44-54, 2014. PMCID: PMC4280356.
18. Denada D, Li S. The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-kappaB1, STAT3, and CD40/CD154. Cell Communication and Signaling 2013, 12/2013. PMCID: PMC3880105.
19. Fang RH, Hu CM, Chen KN, Luk BT, Carpenter CW, Gao W, Li S, Zhang DE, Lu W, Zhang L. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5(19):8884-8, 10/2013. e-Pub 8/2013. PMCID: PMC3831007.
20. Irwin ME, Nelson LD, Santigiao O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Sornblau SM, Hughes DP, Chandra J. Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Phildelphia Chromosome-Positive Acute Lymphoblastic Leukemia. PLoSOne 8(8):e70608, 8/2013. PMCID: PMC3731286.
21. Shiomitsu K, Xia X, Waite K, Sehgal I, Li S. Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro. Open Journal of Veterinary Medicine 3. e-Pub 3/2013.
22. Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of tumor antigen-specific CD8(+) T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 43(2):468-79, 2/2013. e-Pub 1/2013. PMCID: PMC3625660.
23. Cutrera J, Johnson B, Ellis L, Li S. Intraosseous Inoculation of Tumor Cells into Bone Marrow Promotes Distant Metastatic Tumor Development: a Novel Tool for Mechanistic and Therapeutic Studies. Cancer Letters 329(1):68-73, 2/2013. e-Pub 10/2012. PMCID: PMC3535523.
24. Cutrera J, Dibra D, Xia X, Li S. Intricacies for Post-translational tumor-targeted cytokine gene therapy. Mediators of Inflammation 2013(Article ID 378971):9 pages, doi:10.1155/2013/378971, 2013. PMCID: PMC3863455.
25. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 Signaling in Macrophages and CD3 Signaling in T Cells Induces Robust Expression of IL-30. J Immunol 188(8):3709-15, 4/2012. e-Pub 3/2012. PMCID: PMC3324657.
26. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: A novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 55(4):1204-14, 4/2012. e-Pub 3/2012. PMCID: PMC3295919.
27. Flanagan M, Gimble JM, Yu G, Xia X, Bunnell BA, Li S. Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cells. Biol Proced Online 14(1):7, 2012. e-Pub 4/2012. PMCID: PMC3388581.
28. Zolochevska O, Xia X, Williams BJ, Ramsay A,Li S, Figueiredo ML. Sonoporation Delivery of Interleukin-27 Gene Therapy Efficiently Reduces Prostate Tumor Cell Growth In Vivo. Human Gene Therapy, 9/2011. PMID: 21801027.
29. Flanagan M, Gimble JM, Yu G, Wu X, Xia X, Hu J, Yao S, Li S. Competitive electroporation formulation for cell therapy. Cancer Gene Ther 18(8):579-86, 8/2011. e-Pub 6/2011. PMCID: PMC3238913.
30. Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J,Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS ONE 6(8):e23270.doi:10.1371/journal.pone.0023270, 8/2011. PMCID: PMC3154407.
31. Reed SD, Li S. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. Cancer Gene Ther 18(4):265-74, 4/2011. e-Pub 1/2011. PMCID: PMC3415231.
32. Cutrera J, Dibra D, Xia X, Hasan A, Reed S, Li S. Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL12 Gene Therapy. Mol Ther. e-Pub 3/2011. PMCID: PMC3149172.
33. Dibra D, Cutrera J, Xia X, Li S. WSX1 Expression in Tumors Induces Immune Tolerance via Suppression of Effector Immune Cells. PLoS One 6(4):e19072.doi:10.1371/journal.pone.0019072, 2011. e-Pub 4/2011. PMCID: PMC3084744.
34. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 17(7):457-64, 7/2010. e-Pub 2/2010. PMCID: PMC3148143.
35. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol. 184(5):2348-54, 3/2010. PMCID: PMC2824785.
36. Cutrera J, Dibra D, Xia X, Li S. Enhancement of reporter gene detection sensitivity by insertion of specific mini-peptide-coding sequences. Cancer Gene Ther 17(2):131-140, 2/2010. e-Pub 8/2009. PMCID: PMC2808434.
37. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res 69(13):5505-13, 7/2009. e-Pub 6/2009. PMCID: PMC2706921.
38. Shiomitsu K, Sajo E, Xia X, Hunley DW, Mauldin GE,Li S, Mauldin GN. Radiosensitivity of canine osteosarcoma cells transfected with wild-type p53 in vitro. Vet Comp Oncol 6(3):193-200, 9/2008. PMID: 19178679.
39. Craig R, Cutrera J, Zhu S, Xia X, Lee YH,Li S. Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within or into tumors. Mol Ther 16(5):901-6, 5/2008. e-Pub 3/2008. PMID: 18388923.
40. Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 15:13(14):4252-60, 7/2007. PMID: 17634555.
41. Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, Li S,. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 119(9):2113-8, 11/2006. PMID: 16823840.
42. Torrero MN, Xia X, Henk W, Yu S, Li S,. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 66(8):4461-7, 4/2006. PMID: 16618773.
43. Torrero MN, Henk WG,Li S,. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 1(12):257-63, 1/2006. PMID: 16397050.
44. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 12(5):942-9, 11/2005. e-Pub 6/2005. PMID: 15953768.
45. Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A, Bhardwaj A. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther. 11(1):112-9, 1/2005. PMID: 15585412.
46. Li S, Xia X, Mellieon FM, Liu J, Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9(3):347-54, 3/2004. PMID: 15006601.
47. Li S, Hanna E, Breau R, Ratanatharathorn V, Xia X, Suen J. Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs. Br J Cancer 8:90(5):1093-9, 3/2004. PMCID: PMC2409636.
48. Dornhoffer JL, Danner C, Zhou L,Li S. Atrial natriuretic peptide receptor upregulation in the rat inner ear. Annals of Otology, Rhinology and Laryngology 111(11):1040-1044, 11/2002. PMID: 12450181.
49. Wang J, Hamilton JI, Carter MS,Li S, Wilkinson MF. Alternatively spliced TCR mRNA induced by disruption of reading frame. Science 297(5578):108-110, 7/2002. PMID: 12098701.
50. Pumphrey CY, Theus AM,Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62(13):3722-3728, 7/2002. PMID: 12097281.
51. Wang J, Vock VM, Li S, Olivas OR, Wilkinson MF. A quality control pathway that down-regulates aberrant T-cell receptor (TCR) transcripts by a mechanism requiring UPF2 and translation. J Biol Chem 24(277):18489-93, 5/2002. e-Pub 3/2002. PMID: 11889124.
52. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 15(94):762-8, 5/2002. PMID: 12011227.
53. Dornhoffer JL, Danner C, Li S. Natriuretic peptide receptors in the human endolymphatic sac. Arch Otolaryngol Head Neck Surg 128(4):379-83, 4/2002. PMID: 11926910.
54. Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 9(6):390-7, 3/2002. PMID: 11960315.
55. Mühlemann O, Mock-Casagrande CS, Wang J, Li S, Custódio N, Carmo-Fonseca M, Wilkinson MF, Moore MJ. Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol Cell 8(1):33-43, 7/2001. PMID: 11511358.
56. Hanna E, Shrieve DC, Ratanatharathorn V, Xia X, Breau R, Suen J, Li S. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res 15(61):2376-80, 3/2001. PMID: 11289099.
57. Li S, Zhang X, Xia X, Zhou L, Breau R, Suen J, Hanna E. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 8(5):400-7, 3/2001. PMID: 11313817.
58. Hanna E, Zhang X, Woodlis J, Breau R, Suen J, Li S. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 8(3):151-7, 3/2001. PMID: 11332985.
59. Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F, Dean DA, Smith LC. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Ther 8(6):494-7, 3/2001. PMID: 11313829.
60. Li S, MacLaughlin FC, Fewell JG, Li Y, Mehta V, French MF, Nordstrom JL, Coleman M, Belagali NS, Schwartz RJ, Smith LC. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems. Gene Ther 6(12):2005-11, 12/1999. PMID: 10637452.
61. Li S, Wilkinson MF. Site-directed mutagenesis: a two-step method using PCR and DpnI. Biotechniques 23(4):588-90, 10/1997. PMID: 9343667.
62. Li S, Leonard D, Wilkinson MF. T cell receptor (TCR) mini-gene mRNA expression regulated by nonsense codons: a nuclear-associated translation-like mechanism. Journal of Experimental Medicine 185(6):985-992, 1997. PMCID: PMC2196228.
63. Carter MS, Li S, Wilkinson MF. A splicing-dependent regulatory mechanism that detects translation signals. EMBO Journal 15(21):5965-5975, 11/1996. PMCID: PMC452383.
64. Li S, Ke S, Budde RJ. The C-terminal Src kinase (Csk) is widely expressed, active in HT-29 cells that contain activated Src, and its expression is downregulated in butyrate-treated SW620 cells. Cell Biol Int 20(11):723-9, 11/1996. PMID: 8979366.
65. Maiti S, Doskow J,Li S, Nhim RP, Lindsey JS, Wilkinson MF. The Pem homeobox gene. Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing. J Biol Chem 271(29):17536-46, 7/1996. PMID: 8663309.
66. Carter MS, Li S, Wilkinson MF. T cell receptor mRNA regulation: A proofreading mechanism. FASEB Journal 10(6):A-1042, 1996.
67. Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 48(270):28995-9003, 12/1995. PMID: 7499432.
68. Li S, Sun G, Budde RJ. Production and characterization of monoclonal antibodies against the recombinant p50csk protein tyrosine kinase: a tool for signal transduction research. Hybridoma 14(4):341-6, 8/1995. PMID: 8522345.
69. Andrews P, Li S. Partial purification and characterization of galactosidase from cell walls of a nonclimacteris fruit. J Agric. and Food Chemistry(42):2177-2182, 1994.

Invited Articles

1. Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. e-Pub 9/2014. PMID: 25259408.
2. Dibra D, Mishra L, Li S. Molecular Mechanisms of Oncogene-Induced Inflammation and Inflammation-Sustained Oncogene Activation in Gastrointestinal Tumors: an Underappreciated Symbiotic Relationship. Biochimica et Biophysica Acta - Reviews on Cancer 1846(1):152-160, 5/2014. PMCID: PMC4140981.
3. Wang X, Li S. Protein mislocalization: Mechanisms, functions and clinical applications in cancer. Biochimica et Biophysica Acta - Reviews on Cancer 1846(1):13-25, 4/2014. PMCID: PMC4141035.
4. Yan J, Li S. The Role of the Liver in Sepsis. Informa Healthcare, 3/2014.
5. Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 31(6). e-Pub 4/2013. PMCID: PMC3665643.
6. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 9(9):530-8, 9/2012. e-Pub 6/2012. PMCID: PMC3745216.
7. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68(18):3033-46, 9/2011. e-Pub 6/2011. PMCID: PMC3162105.
8. Reed SD,Li S. Electroporation Advances in Large Animals. Curr Gene Ther. e-Pub 8/2009. PMCID: PMC3046614.
9. Craig R, Li S. Function and molecular mechanism of tumor-targeted peptide. Medicinal chemistry(6):109-120, 2006.
10. Li S. Electroporation gene therapy: new developments in vivo and in vitro. Curr Gene Ther 4(3):309-316, 9/2004. PMID: 15384944.
11. Torrero MN,Li S. Growth factor receptors: targets for gene therapy and immunotherapy for cancer treatment. Gene Therapy and Molecular Biology(8):175-180, 2004.
12. Li S, Benninger M. Applications of muscle electroporation gene therapy. Curr Gene Ther 2(1):101-5, 2/2002. PMID: 12108971.
13. Li S. IL-12-Based therapy of malignancies. Drugs of Today 37(9):629-637, 9/2001. PMID: 12743634.
14. Li S, Wilkinson MF. Nonsense surveillance in lymphocytes? Immunity 8(2):135-41, 2/1998. PMID: 9491995.

Book Chapters

1. Hu J, Li S. Electroporation Formulation for Cell Therapy. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 1121, 2nd. Ed(s) J Hu, S Li. Humana Press, 55-60, 2014. ISBN: 978-1-4614-9631-1.
2. Cutrera J, King G, Jones P, Gumpel E, Xia X, Li S. Managing Local Swelling Following Intratumoral Electro-Chemo-Gene Therapy. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 1121, 2nd. Ed(s) J Cutrera, G King, P Jones, E. Gumpel, X Xia, S Li. Humana Press, 233-239, 2014. PMCID: PMC4098855.
3. Hu J, Cutrera J, Li S. The Impact of Non-electrical Factors on Electrical Gene Transfer. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 1121, 2nd. Ed(s) J Hu, J Cutrera, S Li. Humana Press, 47-54, 2014. ISBN: 978-1-4614-9631-1.

Books (edited and written)

1. Li S, Cutrera J, Heller R, Teissie J. Electroporation protocols: Experimental and Clinical Gene Medicine, 2nd. Humana Press, 2014.


1. phone. Lifting the burden of disease” International Innovation, Issue 121 2013 (2051-8528) Research Media, UK pp.26-28, 2013.

Last updated: 4/21/2016